Focus: Dyne Therapeutics is a publicly traded biotech focused on antibody-oligonucleotide conjugate treatments for rare neuromuscular diseases, with a ~300-person workforce based in Waltham, MA.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Growing — net +6 jobs in 30d
21 jobs added vs 15 removed. Steady team buildout.
Strong fit for risk-tolerant professionals seeking early-stage upside in validated rare-disease platform with clear upcoming binary catalysts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dyne Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dyne Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) GuruFocus
DYN Stock Price, Quote & Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) - ChartMill
DYN Stock Price, Quote & Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) ChartMill
Dyne Therapeutics (DYN) director Brian Posner buys 2,000 shares in open market - Stock Titan
Dyne Therapeutics (DYN) director Brian Posner buys 2,000 shares in open market Stock Titan
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - TradingView
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy TradingView
Dyne Therapeutics submits FDA application for muscular dystrophy drug - grafa.com
Dyne Therapeutics submits FDA application for muscular dystrophy drug grafa.com
Experimental Duchenne treatment from Dyne heads to FDA - Stock Titan
Experimental Duchenne treatment from Dyne heads to FDA Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study.
287th ENMC international workshop: Harmonization and federated analysis of myotonic dystrophy registries to model heterogeneous disease trajectories. Hoofddorp, the Netherlands, 28-30 March 2025.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo